Robak T
Department of Hematology, Medical University of Lódź, Poland.
Arch Immunol Ther Exp (Warsz). 1996;44(1):5-9.
Cytokines are involved in hematopoiesis by regulating proliferation, differentiation and cellular functions of various lineages of hematopoietic cells. There is an increasing range of clinical conditions in which cytokines are involved as therapeutic agents. One of the most advanced and successful applications is the stimulation of hematopoiesis by the colony stimulating factors (GM-CSF and G-CSF) and erythropoietin. Hematopoietic growth factors are effective in accelerating recovery from neutropenia after chemotherapy and bone marrow transplantation and in reducing incidence of infections. Interferon alpha (IFN-alpha) proved a useful therapeutic agent for chronic myelogenous and hairy cell leukemias as well as for multiple myeloma and non-Hodgkin's lymphoma. Interleukin 2 is the only cytokine apart from IFN-alpha accepted as antineoplastic agent. It may be useful as adjuvant therapy in the hematological malignancies. It may be supposed that in the near future new recombinant cytokines will be introduced in the treatment of blood diseases.
细胞因子通过调节造血细胞各谱系的增殖、分化和细胞功能参与造血过程。越来越多的临床病症中,细胞因子作为治疗剂发挥作用。最先进且成功的应用之一是集落刺激因子(粒细胞-巨噬细胞集落刺激因子和粒细胞集落刺激因子)和促红细胞生成素对造血的刺激作用。造血生长因子在加速化疗和骨髓移植后中性粒细胞减少的恢复以及降低感染发生率方面有效。α干扰素被证明是治疗慢性粒细胞白血病、毛细胞白血病以及多发性骨髓瘤和非霍奇金淋巴瘤的有效治疗剂。白细胞介素2是除α干扰素外唯一被认可的抗肿瘤细胞因子。它可能作为血液系统恶性肿瘤的辅助治疗手段。可以推测,在不久的将来,新的重组细胞因子将被用于血液疾病的治疗。